Clinical Trials Logo

Infections clinical trials

View clinical trials related to Infections.

Filter by:

NCT ID: NCT05495646 Recruiting - Clinical trials for Catheter-Related Infections

Infection Related to Short-term Central Venous Catheters

Start date: August 8, 2022
Phase:
Study type: Observational

This study aims to evaluate the incidence of infection of short-term central venous catheters by comparing different cannulation techniques (by anatomical references and under ultrasound control) and according to the experience of the operator in patients undergoing elective surgery. A prospective observational study will be carried out in which all scheduled surgery patients who have a central venous line inserted for 12 months will be included. Those under 18 years of age, patients with catheters lasting more than 14 days and those who do not sign the informed consent will be excluded from this study. A chest X-ray will be performed on all patients in order to diagnose possible complications associated with the technique and, only in case of suspected infection, culture of the catheter tip and blood cultures of blood obtained from the catheter and peripheral blood will be requested.

NCT ID: NCT05492539 Recruiting - Clinical trials for Carbapenemase-Producing Enterobacteriaceae

Incidence and Risk Factors for Developing Infections in Patients Colonized by CP-KPC

KPC
Start date: July 1, 2022
Phase:
Study type: Observational

The worldwide increase in the rate of infections due to multidrug-resistant bacteria is considered a major public health problem. Infections caused by carbapenem-resistant Klebsiella pneumoniae (CR-KP) are associated with high morbidity and mortality. Mortality of up to 70% and, in survivors, a readmission rate of up to 72% within 90 days of discharge have been reported. CR-KP infection is usually preceded by colonization. However, the incidence rate and risk factors for CR-KP infections among carriers is poorly understood. Multiple studies have focused in risk factors to develop infections among carriers. In order to identify patients at low risk of CR-KP bloodstream infections, Gianella et at developed a predictive score to stratify patients according to their risk for acquisition of CR-KP infections. However, further studies are needed to validate these results, particularly in high-risk patients, such as haematological patients, solid organ trasplant recipients and patients admitted in ICU. Italian Hospital is an acute tertiary care university teaching hospital with more than 45,000 admission-years, in Buenos Aires, Argentina, with a great proportion of haematological and solid organ transplant recipients, and patients with substantial comorbidities and immunosuppression. With the aim of developing an adequate risk assessment for CR-KP infections among CR-KP carriers, we performed a retrospective cohort analysis, in a tertiary teaching hospital in Buenos Aires, Argentina. The main purpose of our study is to describe the incidence of CR-KP infections among CRKP colonized patients, to demonstrate the risk factors for acquisition of CR-KP infections and to develop a clinical predictive score that could stratify patients to guide therapeutic decisions in CR-KP carriers, and avoid overuse of broad-spectrum therapy.

NCT ID: NCT05488340 Recruiting - Clinical trials for Urinary Tract Infections

A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)

ELIMINATE
Start date: July 13, 2022
Phase: Phase 2
Study type: Interventional

This is a Phase 2 superiority study of LBP-EC01, a recombinant bacteriophage cocktail, with an initial open-label 3-arm pharmacokinetic (PK) lead-in portion of 30 patients to evaluate the optimal dosing regimen to be used in the subsequent 288 patient blinded portion of the study which will be randomized 1:1 comparing LBP-EC01 + antibiotic versus placebo + antibiotic in patients with a history of prior urinary tract infection (UTI) cased by E. coli. All patients will be required to have an active acute uncomplicated UTI at baseline.

NCT ID: NCT05480020 Recruiting - Clinical trials for Microbial Colonization

Probiotic Toothpaste for Microbial Colonization

Start date: August 2022
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the colonization efficacy of probiotic toothpastes in healthy adults

NCT ID: NCT05474430 Recruiting - Clinical trials for Respiratory Infections

Estimating Risk of Respiratory Infections Attributable to CFTR Heterozygosity

Start date: December 20, 2021
Phase:
Study type: Observational

A research team member will brush the inferior surface of the subjects' middle turbinate (nasal cavity) using a cytology brush to obtain the cells needed to perform our functional respiratory assays. An individual trained in phlebotomy will draw one 3 ml lavender top tube of blood to test c-reactive protein, calprotectin, and lactoferrin. They will also draw a 5 ml gold top serum separator tube of blood to test fibroblast growth factor-19. The participant will answer questions from the baseline survey and report their current medications interview-style with the research team member.

NCT ID: NCT05472779 Recruiting - Clinical trials for Recurrent Urinary Tract Infection

Periurethral vs Intravaginal Estrogen for Prevention of Recurrent Urinary Tract Infections

TAPER
Start date: January 3, 2023
Phase: Phase 2
Study type: Interventional

Due to rising antibiotic resistance, there has been a focus on non-antibiotic prophylactic measures for postmenopausal patients with recurrent urinary tract infections (rUTI), one of which is the safe and efficacious option of vaginal estrogen therapy. Standard application of vaginal estrogen cream entails intravaginal application of the cream twice a week, but some providers counsel patients with rUTI to apply a small, pea-sized amount to the periurethral area. This ideally reduces the amount of vaginal estrogen used while attaining a similar effect. However, to date, there is no data to prove that the periurethral technique of application is similar or non-inferior to intravaginal application in preventing UTI.

NCT ID: NCT05471973 Recruiting - Infections Clinical Trials

CIED Infection Quality Initiative Demonstration Project

RECTIFY
Start date: May 10, 2023
Phase: N/A
Study type: Interventional

The aim of this Quality Initiative (QI) demonstration project is to develop a model to increase guideline-driven care for patients with cardiovascular implantable electronic devices (CIED) infection. Multidisciplinary teams will be established to carry out the multifaceted intervention. This program seeks to improve early identification and diagnosis, appropriate treatment, and faster time to treatment of CIED infection.

NCT ID: NCT05471908 Recruiting - Pneumonia Clinical Trials

Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial

FAAN-C
Start date: August 22, 2022
Phase: N/A
Study type: Interventional

Compare the effectiveness of automatic vs as-needed (PRN) post-hospitalization follow-up for children who are hospitalized for common infections.

NCT ID: NCT05471726 Recruiting - Infections Clinical Trials

Improving Post-discharge Antimicrobial Use

Start date: May 22, 2023
Phase: N/A
Study type: Interventional

One in five hospitalized patients is prescribed an antimicrobial at the time of discharge, and a large proportion of these post-discharge antimicrobials are unnecessary. The investigators will evaluate a novel method for reviewing post-discharge antimicrobial prescriptions in real-time with the goal of improving antimicrobial selection and duration.

NCT ID: NCT05471661 Recruiting - Clinical trials for Bone Marrow Transplant Infection

T Lymphocytes for the Treatment of AdV, CMV, EBV, BKV and Aspergillus Fumigatus Infections After Allogeneic Stem Cell Transplantation

Penta-STs-001
Start date: January 24, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is to determine the feasibility, safety and efficacy of administering rapidly-generated donor-derived pentavalent-specific T cells (Penta-STs) to mediate antiviral and antifungal activity in hematopoietic stem cell transplant (HSCT) recipients with AdV, EBV, CMV, BKV or Aspergillus fumigatus (AF) infection/ reactivation or with active disease.